Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Vaccines on trial

Nature volume 436, page 484 (2005)Cite this article

One of the largest ever vaccine studies is under way in Kolkata. Paroma Basu uncovers the benefits, and difficulties, of inoculating 60,000 people against cholera and typhoid fever.

In the poorest areas of this city, residents live in homes jammed together along winding sewage-littered pathways and rely on shared toilets and drinking water. Typhoid fever and cholera are endemic in India, and are chronic problems in Kolkata. Cholera, in particular, has a tenacious grip on the state of West Bengal, often called the ‘homeland of cholera’.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Author information

Author notes

  1. Paroma Basu is a freelance writer based in Madison, Wisconsin.

    • Paroma Basu
Authors
  1. Paroma Basu
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Basu, P. Vaccines on trial. Nature 436, 484 (2005). https://doi.org/10.1038/436484a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/436484a

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing